HomeNGEN • CVE
NervGen Pharma Corp
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 6.81M | 39.61% |
Net income | -8.61M | -0.00% |
Net profit margin | — | — |
Earnings per share | -0.14 | — |
EBITDA | -6.79M | -39.75% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 17.27M | 48.10% |
Total assets | 19.49M | 47.22% |
Total liabilities | 16.91M | 10.92% |
Total equity | 2.58M | — |
Shares outstanding | 70.99M | — |
Price to book | 70.25 | — |
Return on assets | -81.13% | — |
Return on capital | -283.82% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -8.61M | -0.00% |
Cash from operations | -3.66M | -18.58% |
Cash from investing | 25.23K | 2,523,100.00% |
Cash from financing | 310.00K | 314.61% |
Net change in cash | -3.74M | -19.66% |
Free cash flow | 277.73K | -88.22% |
Previous close
$2.81
Day range
$2.80 - $2.91
Year range
$1.65 - $3.36
Market cap
202.88M CAD
Avg Volume
48.22K
P/E ratio
-
Dividend yield
-
Primary exchange
CVE
About
Founded
2017
Headquarters
Website
Employees
10
